Janney Capital analyst Ken Trbovich upgraded Cara Therapeutics to Buy from Neutral and raised his price target for the shares to $27 from $21. With the stock down over 50% from 2017 highs and "major catalysts" for CR845 upcoming, "it's time to Buy" Cara again, Trbovich tells investors in a research note. The analyst believes CR845 is more likely to reach the market first for the treatment of Chronic Kidney Disease-associate Pruritus and now assumes a higher potential selling price in this market. He thinks the stock is worth about $17 per share for the CKDaP indication alone. Trbovich continues to have "diminished confidence" in the outlook for the CLIN3001 Phase 3 study in pain.